Usa.- Taking Viagra does more than improve men’s performance in bed: it can also help people with coronary artery disease live longer and have a lower risk of a new heart attack, according to a new study.
Power problems are common in older men and now our study also shows that PDE5 inhibitors can protect against heart attack and prolong life, said the study’s lead author, Martin Holzmann, an adjunct professor of medicine.
Impotence, also known as erectile dysfunction, may be related to poor blood flow and may be an early warning sign of heart disease in healthy men, the authors noted.
Stay informed about what matters most to you
Get the most relevant news of the day in your e-mail
Thank you for subscribing!
Check your inbox to confirm your email and start getting the latest news
Take advantage and take the next step
Get our news alerts so you don’t miss anything
Receive notifications
Not bad! You’ve subscribed to notifications
Set up and choose your preferences
Set up notifications
Enter your e-mail
Subscribe
Subscribing involves accepting the terms and conditions
Not bad! You’ve subscribed to notifications
Set up and choose your preferences
Subjects began taking some form of erectile dysfunction drug at least six months after their heart attack or heart procedure. Read more: Children keep their distance while protecting themselves from a shooting at a school in BrazilProximatedly 16,500 of the men took Viagra, Cialis or some other PDE5 drug, while the others took injected alprostadil.
Otherwise, it is also known that excess of this drug can have negative effects on the heart of the person who consumes it. Afp
Researchers followed men’s health for an average of nearly six years, during which about 2,800 of them died. Those taking a PDE5 drug had a 12 percent lower risk of dying during that follow-up than men taking alprostadil, the team reported in the Journal of the American College of Cardiology. , heart failure or the need for angioplasty or referral procedure than those who received alprostadil, according to the report, which was not funded by the pharmaceutical industry. Protection depended on the dose, which means that the more often a man used a PDE5 inhibitor, the lower his risk.
Red light to the Calderons
Holzmann warned that the study was not designed to prove a cause-and-effect relationship, saying that other factors might be at stake.
